Comparative Pharmacology
Head-to-head clinical analysis: ALDORIL 15 versus SERPASIL ESIDRIX 2.
Head-to-head clinical analysis: ALDORIL 15 versus SERPASIL ESIDRIX 2.
ALDORIL 15 vs SERPASIL-ESIDRIX #2
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brainstem, decreasing peripheral vascular resistance and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, reducing plasma volume and cardiac output.
Serpasil-Esidrix #2 contains reserpine and hydrochlorothiazide. Reserpine irreversibly inhibits the vesicular monoamine transporter 2 (VMAT2) in the CNS and peripheral sympathetic nerve endings, depleting norepinephrine, dopamine, and serotonin from storage vesicles, leading to reduced sympathetic outflow and antihypertensive effect. Hydrochlorothiazide inhibits the Na+/Cl- cotransporter in the distal renal tubule, increasing excretion of sodium, chloride, and water, thereby reducing plasma volume and peripheral vascular resistance.
1 tablet (hydrochlorothiazide 15 mg, methyldopa 250 mg) orally twice daily; increase as needed up to 2 tablets twice daily.
1 tablet orally once daily. Each tablet contains 0.25 mg reserpine and 50 mg hydrochlorothiazide.
None Documented
None Documented
Terminal half-life: 12–17 hours; clinical context: steady-state achieved within 2–3 days; effect persists 12–24 hours
Reserpine: 50-100 hours (biphasic; terminal phase 11-16 days due to slow release from adrenergic storage sites); Hydrochlorothiazide: 6-15 hours (prolonged in renal impairment).
Renal: ~70% unchanged; biliary/fecal: ~30% as metabolites
Reserpine: 60% renal (as metabolites), 40% fecal (as parent drug and metabolites); Hydrochlorothiazide: >95% renal (unchanged) via tubular secretion.
Category C
Category C
Antihypertensive Combination
Antihypertensive Combination